ransactions contemplated by the Transaction Agreement; access to available financing (including financing for the transactions contemplated by the Transaction Agreement) on a timely basis and on reasonable terms; the risks and uncertainties normally incident to the pharmaceutical industry, including product liability claims and the availability of product liability insurance; market acceptance of and continued demand for Perrigo's, New Perrigo's and Elan's products; changes in tax laws or interpretations that could increase Perrigo's or the combined company's consolidated tax liabilities; and such other risks and uncertainties detailed in Perrigo's, Elan's and New Perrigo's periodic public filings with the SEC, including but not limited to those discussed under "Risk Factors" in Perrigo's Form 10-K for the fiscal year ended June 29, 2013, Elan's Annual Report on Form 20-F for the fiscal year ended December 31, 2012 and New Perrigo's Registration Statement on Form S-4/A filed on October 8, 2013, in Perrigo's, Elan's and New Perrigo's subsequent filings with the SEC and in other investor communications of Perrigo, Elan and New Perrigo from time to time.
The forward looking statements in this announcement are made only as of the date hereof, and unless otherwise required by applicable securities laws, Perrigo, Elan and New Perrigo disclaim any intention or obligation to update or revise any forward looking statements, whether as a result of new information, future events or otherwise.
No Offer or SolicitationPage: 1 2 3 4 5 6 7 Related biology technology :1
This announcement is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securiti
. Perrigo Files Registration Statement On Form S-4 In Connection With Proposed Acquisition Of Elan2
. Perrigo Company to Present at the UBS Global Life Sciences Conference3
. Perrigo Reports Record Fourth Quarter and Fiscal Year Revenue, Earnings and Cash Flow From Operations4
. Perrigo Receives FDA Approval And Commences Launch Of Morphine Sulfate 100ml/5% Oral Solution5
. Tastes Change, But One Company Trends First with Their Sweetest Solution6
. Myriant Selected as a 2013 Red Herring Top 100 Global Company7
. Systems Upgrade Keeps Neurotechnology Company on the Leading Edge8
. Clinovo Ranked #9 Among 494 Biotech by Business Intelligence Company SIGNL9
. Genesis Herb Company Selects InstantGMP as their Manufacturing Execution System with Electronic Batch Records10
. DunhamTrimmer LLC Is the Premier Market Research Company11
. Colby Pharmaceutical Company Announces Dramatic Results: Novel Technology Increases Influenza Vaccine Protection for Elderly Rhesus Monkeys